Beta Drugs Limited has informed the Exchange about statement of deviation(s) or variation(s) under Reg. 32
BETA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Beta Drugs Limited has filed a statement confirming no deviation or variation in the use of proceeds from its preferential issue that raised Rs 117.01 crores in November 2024. The statement was reviewed by the Audit Committee and approved by the Board of Directors on May 14, 2026. As of March 31, 2026, the company has utilized Rs 23.87 crores (about 20%) of the total funds raised. The largest allocation of Rs 44 crores was for capital expenditure on new manufacturing setup, of which Rs 9.52 crores has been utilized. Rs 20 crores was allocated for capital investment including acquisitions, but no funds have been deployed yet. The monitoring agency for this issue is Brickwork Ratings India Private Limited.
This is a routine compliance filing confirming proper use of IPO/preferential issue proceeds as per stated objects. No deviation detected — a positive signal indicating fund management discipline. However, the relatively low utilization rate (20%) suggests the company is still in the early phases of its expansion and capital expenditure plans.